This article first appeared on GuruFocus.

Aquestive Therapeutics Inc (NASDAQ:AQST) is set to release its Q3 2025 earnings on Nov 5, 2025. The consensus estimate for Q3 2025 revenue is $12.94 million, and the earnings are expected to come in at -$0.13 per share. The full year 2025's revenue is expected to be $44.98 million and the earnings are expected to be -$0.64 per share. More detailed estimate data can be found on the Forecast page.

Warning! GuruFocus has detected 7 Warning Signs with AQST.

Is AQST fairly valued? Test your thesis with our free DCF calculator.

Over the past 90 days, revenue estimates for Aquestive Therapeutics Inc (NASDAQ:AQST) have declined from $45.06 million to $44.98 million for the full year 2025, and from $68.32 million to $68.10 million for 2026. Meanwhile, earnings estimates have increased from -$0.71 per share to -$0.64 per share for the full year 2025, and from -$0.59 per share to -$0.57 per share for 2026.

In the previous quarter ending 2025-06-30, Aquestive Therapeutics Inc's (NASDAQ:AQST) actual revenue was $10.00 million, which missed analysts' revenue expectations of $11.32 million by -11.63%. Aquestive Therapeutics Inc's (NASDAQ:AQST) actual earnings were -$0.14 per share, which beat analysts' earnings expectations of -$0.171 per share by 18.13%. After releasing the results, Aquestive Therapeutics Inc (NASDAQ:AQST) was down by -2.07% in one day.

Based on the one-year price targets offered by 9 analysts, the average target price for Aquestive Therapeutics Inc (NASDAQ:AQST) is $8.97 with a high estimate of $15.00 and a low estimate of $4.75. The average target implies an upside of 38.46% from the current price of $6.48.

Based on GuruFocus estimates, the estimated GF Value for Aquestive Therapeutics Inc (NASDAQ:AQST) in one year is $2.19, suggesting a downside of -66.20% from the current price of $6.48.

Based on the consensus recommendation from 10 brokerage firms, Aquestive Therapeutics Inc's (NASDAQ:AQST) average brokerage recommendation is currently 1.8, indicating an \\"Outperform\\" status. The rating scale ranges from 1 to 5, where 1 signifies strong buy, and 5 denotes sell.